Dihexa
CAS No. 1401708-83-5
Dihexa( PNB-0408 | N-hexanoic-Try-Ile-(6)-amino hexanoic amide | Hexanoyl-Tyr-Ile-Ahx-NH2 )
Catalog No. M20716 CAS No. 1401708-83-5
Dihexa is an activator of the hepatocyte growth factor/c-Met (HGF/c-Met) systemit binds to HGF (Kd = 65 pM)and an analog of the peptide angiotensin IV.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 81 | In Stock |
|
| 5MG | 122 | In Stock |
|
| 10MG | 206 | In Stock |
|
| 25MG | 428 | In Stock |
|
| 50MG | 626 | In Stock |
|
| 100MG | 889 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDihexa
-
NoteResearch use only, not for human use.
-
Brief DescriptionDihexa is an activator of the hepatocyte growth factor/c-Met (HGF/c-Met) systemit binds to HGF (Kd = 65 pM)and an analog of the peptide angiotensin IV.
-
DescriptionDihexa is an activator of the hepatocyte growth factor/c-Met (HGF/c-Met) systemit binds to HGF (Kd = 65 pM)and an analog of the peptide angiotensin IV.
-
In Vitro——
-
In Vivo——
-
SynonymsPNB-0408 | N-hexanoic-Try-Ile-(6)-amino hexanoic amide | Hexanoyl-Tyr-Ile-Ahx-NH2
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
RecptorHGF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1401708-83-5
-
Formula Weight504.66
-
Molecular FormulaC27H44N4O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:30 mg/mL (59.45 mM)
-
SMILESCCCCCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCCCCCC(N)=O
-
Chemical Name6-[(2S3S)-2-[(2S)-2-hexanamido-3-(4-hydroxyphenyl)propanamido]-3-methylpentanamido]hexanamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Capmatinib hydrochlo...
Capmatinib hydrochloride is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Capmatinib was found to be highly selective for MET over other kinases.?It was active against cancer models that are characterized by MET amplification, marked MET overexpression, MET exon 14 skipping mutations, or MET activation via expression of the ligand hepatocyte growth factor (HGF).
-
Tyrosine kinase inhi...
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
-
Amivantamab
Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET).
Cart
sales@molnova.com